Endocyclic Therapeutics secured IND clearance from the FDA for ENDO‑205, a targeted, nonhormonal peptide therapeutic for endometriosis. The company positions ENDO‑205 as a first‑in‑class approach aimed at disease biology without systemic hormonal modulation. Endometriosis affects reproductive‑aged people and current treatments often rely on hormones; a nonhormonal targeted peptide could offer an alternative mechanism. The IND clears the path for first‑in‑human trials and clinical proof‑of‑concept efforts.